skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Infliximab (Code C1789)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Infliximab

Definition: A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)

NCI-GLOSS Definition: A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Display Name: Infliximab

Label: Infliximab

NCI Thesaurus Code: C1789 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0666743  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 170277-31-3 (see NLM ChemIDplus info)
NSC Code 728729 (see NCI DTP info)
PDQ Closed Trial Search ID 38698
PDQ Open Trial Search ID 38698 (check for NCI PDQ open clinical trial info)
UMLS CUI C0666743

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Ankylosis spondylitis; Crohns disease; Plaque psoriasis; Rheumatoid arthritis; Sarcoidosis
code C1789
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Infliximab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom